Altana AG
Altana AG :ALTANA Has Withdrawn EU Marketing Authorisation Applic. for Daxas
Ad hoc announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————
Bad Homburg, November 15, 2005 – ALTANA (NYSE: AAA; FSE: ALT) today announced
that it has withdrawn the European Marketing Authorisation Application (MAA)
for Daxas(R) (roflumilast).
ALTANA Pharma has taken this decision after consulting with the EMEA today.
The submission of a new MAA will be pursued, after further clinical data are
available.
ALTANA Pharma is committed to continue the development of Daxas(R) and will
pursue further clinical studies to strengthen the anti-inflammatory product
profile and possible market potential of Daxas(R).
The phosphodiesterase4 (PDE4)-inhibitor Daxas(R) (roflumilast) is an oral
investigational, steroid free anti-inflammatory agent being studied for the
treatment of chronic obstructive pulmonary disease (COPD) and asthma.
Altana AG
Am Pilgerrain 15
61352 Bad Homburg
Deutschland
ISIN: DE0007600801 (DAX)
WKN: 760080
Listed: Amtlicher Markt in Berlin-Bremen, Düsseldorf und Frankfurt (Prime
Standard); Freiverkehr in Hamburg, Hannover, München und Stuttgart
End of ad hoc announcement (c)DGAP 15.11.2005
Issuer’s information/explanatory remarks concerning this ad hoc announcement:
For inquiries:
Dr. Thomas Gauly
Head of Corporate Communications &
Investor Relations
Media Relations:
P +49 (0) 6172 1712-160
P +49 (0) 6172 1712-168
F +49 (0) 6172 1712-158
Investor Relations:
P +49 (0) 6172 1712-163
P +49 (0) 6172 1712-165
F +49 (0) 6172 1712-158
Investor Relations USA:
P +1 212 974-6192
F +1 212 974-6190
End of message (c)DGAP
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found